Introduction/Background The prevalence of atypical endometrial hyperplasia and endometrial cancer is escalating worldwide in parallel to the epidemic of obesity. In turn, endometrial cancer is being increasingly diagnosed at an earlier age which makes fertility preservation important in these patients. A limited number of studies have reported the outcome of atypical hyperplasia and endometrial cancer in young premenopausal women undergoing fertility sparing treatment. The aim of this study was to analyze the outcome of patients undergoing fertility sparing treatment for atypical hyperplasia and carcinoma endometrium.

Methodology A retrospective study of 19 patients who received fertility sparing treatment for atypical endometrial hyperplasia and carcinoma endometrium from January 2010 to December 2021. Clinical information and follow up data till September 2023 were collected from medical records.

Results The median follow - up period was 60 months. The median age was 32 years. While 8 patients (42.10%) were diagnosed with atypical endometrial hyperplasia, 11 (57.90%) had carcinoma endometrium. Among them 15 patients (78.94%) received high dose oral progesterone, 4 (21.05%) received both high dose oral progesterone and progesterone containing IUD. Thirteen patients (76.47%) responded to treatment among whom 7 women achieved pregnancy with 7 live births and one abortion. Four patients (23.52%) did not respond to hormonal treatment or progressed during treatment and were advised hysterectomy. Two patients requested hysterectomy while on progesterone.

Conclusion Fertility preservation appears feasible in young patients with carcinoma endometrium or atypical endometrial hyperplasia.

Disclosures No conflict of interest to declare.